Protagenic Therapeutics’ Innovative Peptide PT00114 to be Highlighted at Boston Summit
Accesswire
*Chief Operating Officer to Present Key Advances at Peptide Therapeutics Summit*
*NEW YORK, NY / ACCESSWIRE / April 17,..
*Chief Operating Officer to Present Key Advances at Peptide Therapeutics Summit*
*NEW YORK, NY / ACCESSWIRE / April 17,..
TNX-102 SL is a Non-Opioid Analgesic that Demonstrated Daily Pain Reduction Over Placebo (Primary Endpoint, p = 0.00005) and Showed..
*JERSEY CITY, NJ / ACCESSWIRE / July 25, 2023 /* Amdocs (NASDAQ:DOX), a leading provider of software and services to communications..